RxDoctor Payments Data

Amanda McGee

Family · Morganton, NCNPI 1962492082

Payments from drug & device makers

$6,142in general payments, 2019–2025

Across 431 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$891
  • Pfizer$586
  • Lilly USA, LLC$561
  • Teva Pharmaceuticals USA, Inc.$473
  • AstraZeneca$425
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$6,130100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,142 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$39,074
Medicare patients
102
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine29$150,844
EliquisApixaban135$86,140
LinzessLinaclotide111$68,826
OzempicSemaglutide50$61,484
JardianceEmpagliflozin70$55,090
MounjaroTirzepatide50$51,346
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$50,406
Breo ElliptaFluticasone/Vilanterol105$44,918
TrulicityDulaglutide27$34,111
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$32,527
RybelsusSemaglutide26$32,104
VraylarCariprazine Hcl22$29,839
JanuviaSitagliptin Phosphate45$25,858
FarxigaDapagliflozin Propanediol30$25,401
CaplytaLumateperone Tosylate13$23,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$473$150,84429 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$88$102,799189 claims
AbbVieLinzess, Vraylar$1,169$98,665133 claims
Novo NordiskOzempic, Rybelsus$891$93,58876 claims
PfizerEliquis$586$86,140135 claims
Lilly USA, LLCMounjaro, Trulicity$561$85,45777 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$58$74,826109 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$425$68,052101 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$63$23,25713 claims
Johnson & JohnsonXarelto$14$18,14532 claims
Astellas Pharma US IncMyrbetriq$102$17,58936 claims
BayerKerendia$144$7,16512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Morganton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →